Golan Shani, Goldenberg Daphna, Goldstein Michaella
Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel-Aviv, Israel.
Case Rep Ophthalmol. 2011 Sep;2(3):387-91. doi: 10.1159/000334788. Epub 2011 Dec 13.
To present the long-term effect of intravitreal bevacizumab (Avastin(®)) therapy in a patient suffering from retinal arterial macroaneurysm.
Case report of a 72-year-old female diagnosed with retinal macroaneurysm in the superior temporal artery leading to macular edema. Functional and morphological data at baseline, 4 weeks, 2 months, and 13 months following treatment with two consecutive intravitreal bevacizumab injections are presented.
Best-corrected visual acuity improved from 20/160 at baseline to 20/20 at the 3-months follow-up and remained stable through 13 months of follow-up. Central retinal thickness measured by optical coherence tomography decreased from 364 μm at baseline to 248 μm at the 13-months follow-up. No ocular or systemic side effects were detected.
Intravitreal bevacizumab therapy may lead to resolution of macular edema associated with retinal macroaneurysm and consequently visual improvement. This treatment may promise a long-lasting effect but warrant further investigation in larger series.
介绍玻璃体内注射贝伐单抗（阿瓦斯汀®）治疗视网膜动脉大动脉瘤患者的长期疗效。
报告一例72岁女性患者，其颞上动脉诊断为视网膜大动脉瘤并导致黄斑水肿。呈现了连续两次玻璃体内注射贝伐单抗治疗后基线、4周、2个月和13个月时的功能和形态学数据。
最佳矫正视力从基线时的20/160提高到3个月随访时的20/20，并在13个月的随访中保持稳定。光学相干断层扫描测量的中央视网膜厚度从基线时的364μm降至13个月随访时的248μm。未检测到眼部或全身副作用。
玻璃体内注射贝伐单抗治疗可能导致与视网膜大动脉瘤相关的黄斑水肿消退，从而改善视力。这种治疗可能具有持久效果，但需要在更大系列中进行进一步研究。
